Jorge Matias Caviglia1, Jun Yan1,2, Myoung-Kuk Jang1,3, Geum-Youn Gwak1,4, Silvia Affo1, Lexing Yu1, Peter Olinga5, Richard A Friedman6, Xin Chen7, Robert F Schwabe1. 1. Department of Medicine, Columbia University, New York, NY. 2. Department of Pathology, Tianjin First Center Hospital, Tianjin, China. 3. Department of Gastroenterology and Hepatology, Internal Medicine, Kangdong Sacred Heart Hospital of Hallym University Medical Center, Seoul, South Korea. 4. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 5. Division of Pharmaceutical Technology and Biopharmacy, Department of Pharmacy, University of Groningen, Groningen, the Netherlands. 6. Biomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer Center and Department of Biomedical Informatics, Columbia University, New York, NY. 7. Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California San Francisco, San Francisco, CA.
Abstract
Fibrosis and cancer represent two major complications of chronic liver disease. MicroRNAs have been implicated in the development of fibrosis and cancer, thus constituting potential therapeutic targets. Here, we investigated the role of microRNA-21 (miR-21), a microRNA that has been implicated in the development of fibrosis in multiple organs and has also been suggested to act as an "oncomir." Accordingly, miR-21 was the microRNA that showed the strongest up-regulation in activated hepatic stellate cells (HSCs) in multiple models of fibrogenesis, with an 8-fold to 24-fold induction compared to quiescent HSCs. However, miR-21 antisense inhibition did not suppress the activation of murine or human HSCs in culture or in liver slices. Moreover, genetic deletion of miR-21 in two independently generated knockout mice or miR-21 antisense inhibition did not alter HSC activation or liver fibrosis in models of toxic and biliary liver injury. Despite a strong up-regulation of miR-21 in injury-associated hepatocellular carcinoma and in cholangiocarcinoma, miR-21 deletion or antisense inhibition did not reduce the development of liver tumors. As inhibition of the most up-regulated microRNA did not affect HSC activation, liver fibrosis, or fibrosis-associated liver cancer, we additionally tested the role of microRNAs in HSCs by HSC-specific Dicer deletion. Although Dicer deletion decreased microRNA expression in HSCs and altered the expression of select genes, it only exerted negligible effects on HSC activation and liver fibrosis. CONCLUSION: Genetic and pharmacologic manipulation of miR-21 does not inhibit the development of liver fibrosis and liver cancer. Moreover, suppression of microRNA synthesis does not significantly affect HSC phenotype and activation. (Hepatology 2018;67:2414-2429).
Fibrosis and cancer represent two major complications of chronic liver disease. MicroRNAs have been implicated in the development of fibrosis and cancer, thus constituting potential therapeutic targets. Here, we investigated the role of microRNA-21 (miR-21), a microRNA that has been implicated in the development of fibrosis in multiple organs and has also been suggested to act as an "oncomir." Accordingly, miR-21 was the microRNA that showed the strongest up-regulation in activated hepatic stellate cells (HSCs) in multiple models of fibrogenesis, with an 8-fold to 24-fold induction compared to quiescent HSCs. However, miR-21 antisense inhibition did not suppress the activation of murine or human HSCs in culture or in liver slices. Moreover, genetic deletion of miR-21 in two independently generated knockout mice or miR-21 antisense inhibition did not alter HSC activation or liver fibrosis in models of toxic and biliary liver injury. Despite a strong up-regulation of miR-21 in injury-associated hepatocellular carcinoma and in cholangiocarcinoma, miR-21 deletion or antisense inhibition did not reduce the development of liver tumors. As inhibition of the most up-regulated microRNA did not affect HSC activation, liver fibrosis, or fibrosis-associated liver cancer, we additionally tested the role of microRNAs in HSCs by HSC-specific Dicer deletion. Although Dicer deletion decreased microRNA expression in HSCs and altered the expression of select genes, it only exerted negligible effects on HSC activation and liver fibrosis. CONCLUSION: Genetic and pharmacologic manipulation of miR-21 does not inhibit the development of liver fibrosis and liver cancer. Moreover, suppression of microRNA synthesis does not significantly affect HSC phenotype and activation. (Hepatology 2018;67:2414-2429).
Authors: Inge A M de Graaf; Peter Olinga; Marina H de Jager; Marjolijn T Merema; Ruben de Kanter; Esther G van de Kerkhof; Geny M M Groothuis Journal: Nat Protoc Date: 2010-08-19 Impact factor: 13.491
Authors: David M Patrick; Rusty L Montgomery; Xiaoxia Qi; Susanna Obad; Sakari Kauppinen; Joseph A Hill; Eva van Rooij; Eric N Olson Journal: J Clin Invest Date: 2010-10-18 Impact factor: 14.808
Authors: Jennifer Y Lai; Jinghui Luo; Christopher O'Connor; Xiaohong Jing; Viji Nair; Wenjun Ju; Ann Randolph; Iddo Z Ben-Dov; Regina N Matar; Daniel Briskin; Jiri Zavadil; Robert G Nelson; Thomas Tuschl; Frank C Brosius; Matthias Kretzler; Markus Bitzer Journal: J Am Soc Nephrol Date: 2014-08-21 Impact factor: 10.121
Authors: Florin M Selaru; Alexandru V Olaru; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Jian Yang; Bogdan Paun; Zhe Jin; Rachana Agarwal; James P Hamilton; John Abraham; Christos Georgiades; Hector Alvarez; Perumal Vivekanandan; Wayne Yu; Anirban Maitra; Michael Torbenson; Paul J Thuluvath; Gregory J Gores; Nicholas F LaRusso; Ralph Hruban; Stephen J Meltzer Journal: Hepatology Date: 2009-05 Impact factor: 17.425
Authors: Samuele De Minicis; Ekihiro Seki; Hiroshi Uchinami; Johannes Kluwe; Yonghui Zhang; David A Brenner; Robert F Schwabe Journal: Gastroenterology Date: 2007-02-21 Impact factor: 22.682
Authors: Cody Orr; Rob Myers; Biao Li; Zhaoshi Jiang; John Flaherty; Anuj Gaggar; Eric G Meissner Journal: Liver Int Date: 2020-05-02 Impact factor: 5.828